Abstract: Sodium oxamate is a well-known competitive inhibitor of lactate dehydrogenase A (LDHA) that has emerged as a promising candidate for metabolic cancer therapy. Beyond its direct metabolic effects on tumor cells, recent evidence highlights its profound impact on inflammation and the tumor microenvironment (TME), particularly concerning macrophage polarization. By reducing lactate production, oxamate reverses lactate-driven immunosuppression and modulates myeloid cell polarization. Notably, oxamate exhibits a context- and dose-dependent effect on macrophages, promoting an immunosuppressive M2 phenotype at low doses and a pro-inflammatory M1 phenotype at high doses. This review synthesizes the pharmacological activity, molecular mechanisms, structure-activity relationship, current limitations, and future perspectives of sodium oxamate in the context of inflammation and macrophage polarization.
1. Introduction
Lactate dehydrogenase (LDH) is a critical glycolytic enzyme catalyzing the interconversion of pyruvate and lactate. The LDHA isoform is frequently overexpressed in various malignancies, driving the Warburg effect and promoting rapid ATP production and lactate accumulation [1]. The resulting acidic tumor microenvironment (TME) not only favors tumor invasion but also facilitates immune evasion by suppressing anti-tumor immune responses [1]. Lactate acts as a key signaling molecule that regulates immune cell function through metabolic and epigenetic mechanisms, including the modulation of macrophage polarization [1]. Sodium oxamate, a pharmacological inhibitor of LDHA, has shown substantial potential in counteracting these effects. While traditionally viewed through the lens of metabolic blockade, oxamate is increasingly recognized for its dual effects on tumor metabolism and anti-tumor immunity, specifically its ability to reshape inflammation and myeloid cell polarization within the TME [1].
2. Pharmacological Activity
Oxamate exerts significant immunomodulatory activity by reversing lactate-driven immunosuppression in the TME [1]. Elevated lactate typically suppresses cytotoxic T lymphocyte (CTL) activity and promotes regulatory T cell (Treg) function. By inhibiting LDHA, oxamate reduces TME acidity, thereby restoring the functionality of CTLs and enhancing the protective function of chimeric antigen receptor-T (CAR-T) cells, leading to increased production of interferon-gamma (IFNγ), perforin, and granzyme B [1]. Crucially, oxamate profoundly impacts macrophage polarization. In tumor models, tumor-derived lactate stimulates macrophages to adopt an immunosuppressive M2 phenotype, characterized by increased arginase-1 (Arg-1) activity and mannose receptor C-type 1 expression [1]. Oxamate treatment prevents this M2 polarization. Interestingly, the effect of oxamate on macrophages is highly dose-dependent. At low doses, oxamate activates M2 macrophage markers, increasing Arg-1 activity and decreasing nitric oxide (NO) synthase activity. Conversely, high doses of oxamate drive macrophages toward a pro-inflammatory M1 polarization, characterized by increased NO synthase activity and decreased Arg-1 activity [1].
3. Molecular Mechanism of Action
The immunomodulatory and anti-inflammatory effects of oxamate are primarily secondary to its inhibition of tumor-derived lactate production [1]. By competitively inhibiting LDHA, oxamate decreases lactate synthesis and disrupts NAD+ regeneration, which normalizes the pH of the TME [1]. This metabolic shift epigenetically suppresses key immunoregulatory genes (such as CD39, CD73, and CCR8) by reducing histone lactylation (HKla) on their promoters [1]. Regarding macrophage polarization, oxamate inhibits the signaling pathways hijacked by lactate. Specifically, it reduces Akt/extracellular signal-regulated kinase (ERK) pathway activation, which is otherwise responsible for driving M2 polarization [1]. Additionally, oxamate prevents M2 macrophage polarization by interfering with the monocarboxylate transporter (MCT)-HIF1α signaling axis [1].
4. Structure-Activity Relationship (SAR)
The inhibitory mechanism of sodium oxamate is fundamentally based on its structural resemblance to pyruvate, the natural substrate of LDHA [1]. Both molecules share a carboxylate group, which is essential for binding. However, oxamate is distinguished by the presence of an amide substituent in place of the methyl group found in pyruvate [1]. This specific structural similarity allows oxamate to act as a competitive inhibitor, effectively occupying the active site of the LDHA enzyme and preventing the normal conversion of pyruvate to lactate [1].
5. Current Limitations
Despite its efficacy in preclinical models, the clinical translation of sodium oxamate faces significant pharmacokinetic and physicochemical hurdles. Oxamate is highly polar due to the presence of its carboxyl and amide groups, which ionize at physiological pH [1]. This high polarity results in poor passive diffusion across lipid cell membranes, severely limiting its cellular permeability and systemic efficacy [1]. Furthermore, its hydrophilicity leads to rapid renal excretion and a short plasma half-life [1]. Unlike some lactate analogs, oxamate is not taken up by specialized membrane transporters. Consequently, extremely high concentrations (typically 10–200 mM) are required in vitro and in vivo to successfully compete with intracellular pyruvate for the LDHA active site and to overcome the metabolic plasticity of tumor cells [1].
6. Future Perspectives
To overcome the clinical barriers associated with oxamate's high polarity and poor membrane permeability, future strategies are heavily focused on nanomedicine [1]. Encapsulating oxamate within nanoparticles (NPs), such as liposomes or niosomes, can shield its polar groups and facilitate transmembrane transport via endocytosis, significantly improving intracellular drug delivery [1]. Functionalized NPs can also achieve active targeting of tumor tissues, reducing systemic toxicity and increasing the local concentration of oxamate to modulate the TME and macrophage polarization effectively [1]. Additionally, rational combination regimens—pairing oxamate with immunotherapies (like anti-PD-1 agents) or other metabolic inhibitors—hold great promise for circumventing resistance and maximizing anti-tumor immunity [1].
